Next |
home / stock / kura / kura message board
Subject | By | Source | When |
---|---|---|---|
* * $KURA Video Chart 04-28-2020 * * | ClayTrader | investorshub | 04/28/2020 9:04:32 PM |
Anybody out there? ! | seppi08162 | investorshub | 12/19/2019 5:52:35 PM |
KURA buy 19.00 | stocktrademan | investorshub | 02/11/2018 5:50:43 PM |
Feels risky here...feels like they're purposely notching it | Lone Wolf | investorshub | 09/08/2017 3:17:02 PM |
Looks like the markets are really starting to | Lone Wolf | investorshub | 09/08/2017 2:26:26 PM |
Just got in hope not to late | jr525 | investorshub | 09/08/2017 2:04:08 PM |
Looking KBIO-like squeezish!! ;-) | Lone Wolf | investorshub | 09/08/2017 2:01:26 PM |
Why's that? Now it's up 60%! | Lone Wolf | investorshub | 09/08/2017 1:49:49 PM |
May go for a ride during regular hours | sorkin | investorshub | 09/08/2017 1:19:31 PM |
Don't get sucked in buying this @30% premium | sorkin | investorshub | 09/08/2017 12:57:18 PM |
$kura long@ 8.28 | Bearly Bullish | investorshub | 06/07/2017 12:55:02 PM |
KURA bullish 10.10 | stocktrademan | investorshub | 04/15/2017 5:27:48 PM |
KURA $5.89 | ClearlyStocks | investorshub | 08/30/2016 7:52:25 PM |
KURA $5.75 | ClearlyStocks | investorshub | 08/30/2016 4:57:11 PM |
KURA $5.66 on radar | ClearlyStocks | investorshub | 08/30/2016 4:05:52 PM |
Getting close - watch for the turn up | stock_observer_77 | investorshub | 08/18/2016 1:35:06 AM |
* * $KURA Video Chart 08-11-16 * * | ClayTrader | investorshub | 08/11/2016 9:04:19 PM |
Come to Poppa | INTL | investorshub | 08/11/2016 3:11:15 PM |
$13,000 for me:) | Goldmind | investorshub | 08/11/2016 2:13:23 PM |
Weeeeeeeee | Goldmind | investorshub | 08/11/2016 2:08:50 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizi...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the cl...
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOB...